KAPANYSEPharmaceutical PreparationsFiscal year ends December 31

Kairos Pharma, LTD.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.57−0.03 (-5.19%)

Close on Oct 19, 2026

Market cap: $12.21M
P/E (TTM): –
Dividend yield: –

Kairos Pharma, LTD. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research & Development	2.14	0.41	0.08
General & Administrative	3.44	1.93	1.63
Operating Expenses	5.57	2.34	1.71
Operating Income	-5.57	-2.34	-1.71
Interest Expense	–	0.04	0.04
Other Non-Operating Income	0.13	-0.26	-0.10
Net Income	-5.45	-2.60	-1.81
EPS (Basic)(per share)	-0.30	-0.23	-0.17
EPS (Diluted)(per share)	-0.30	-0.23	-0.17
Shares Outstanding (Basic, Weighted)(shares)	18	11	10
Shares Outstanding (Diluted, Weighted)(shares)	18	11	10

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -98.0%

Financial strength

Current ratio: 11.98
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 990.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.91
Dividend yield: –